<DOC>
	<DOCNO>NCT02640534</DOCNO>
	<brief_summary>The purpose trial test combination enzalutamide metformin patient castration resistant prostate cancer CRPC progress androgen deprivation therapy ADT effective compare enzalutamide alone . The half patient receive experimental treatment combination , enzalutamide metformin , half receive enzalutamide alone .</brief_summary>
	<brief_title>Investigation Metformin Patients With Castration Resistant Prostate Cancer Combination With Enzalutamide vs. Enzalutamide Alone</brief_title>
	<detailed_description>One seven men diagnose cancer prostate lifetime . Accordingly , prostate cancer ( PC ) common cancer amongst men western world worldwide . PC rank second cancer incidence sixth cancer mortality men . The current standard care patient metastatic castration resistant prostate cancer ( mCRPC ) disease progression either treatment abiraterone acetate prednisone asymptomatic mildly symptomatic patient without visceral metastasis , treatment docetaxel symptomatic patient presence visceral metastasis . Rothemundt et al . previously demonstrate favorable effect metformin phase II trial : yield objective Prostate specific antigen PSA response may induce disease stabilization improve metabolic endpoint patient CRPC . Therefore addition metformin enzalutamide might positive impact tumor progression , body composition , insulin sensitivity .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Written inform consent accord ICH/GCP regulation registration prior trialrelated investigation Histologically cytological confirm adenocarcinoma prostate without small cell feature Asymptomatic minimally symptomatic patient relation disease Metastatic adenocarcinoma prostate document imaging ( CT/MRI and/or bone scan ) Ongoing androgen deprivation therapy Gonadotropinreleasing hormone GnRH analogues bilateral orchiectomy ( i.e . surgical medical castration ) Total testosterone level ≤ 1.7 nmol/L ( correspond ≤ 50 ng/dL ) Tumor progression time registration , define per protocol . Completed baseline QoL pain questionnaire Male patient ≥ 18 year WHO performance status 02 Adequate hematologic value : hemoglobin ≥ 90 g/L , neutrophils ≥ 1.0 x 109/L , platelet ≥ 75 x 109/L Adequate hepatic function : ALT AST ≤ 2.5 x ULN , bilirubin ≤ 1.5 x ULN ( exception Gilbert 's syndrome ≤ 2.5 x ULN ) Adequate renal function : calculated creatinine clearance ≥ 50 mL/min , accord formula CockcroftGault Patient able swallow trial drug comply trial requirement Patient agree father child participation trial 3 month thereafter Patient agree participate mandatory translational research part trial exception Pyruvate dehydrogenase substudy . Known suspected Central nervous system CNS metastases active leptomeningeal disease Previous malignancy within 2 year prior registration , exception localize nonmelanoma skin cancer Ta Tis bladder cancer Prior treatment prostate cancer novel endocrine agent ( include abiraterone acetate , enzalutamide , TAK700 , TAK683 , TAK448 , VT464 , ODM201 , ARN509 ) , radioisotopes , TKI small molecule , immunotherapy chemotherapy ( exception docetaxel chemotherapy hormone sensitive prostate cancer ) Treatment experimental drug treatment within clinical trial within 30 day prior registration ( except clinical trial SAKK 96/12 and/or biobank project SAKK 63/12 ) Clinically significant cardiovascular disease include : Myocardial infarction within 6 month prior registration , Uncontrolled angina within 3 month prior registration , Congestive heart failure NYHA class III IV , QTc interval &gt; 480 m , History clinically significant ventricular arrhythmia ( e.g . ventricular tachycardia , ventricular fibrillation , torsades de pointes ) , History Mobitz II second third degree heart block without permanent pacemaker place , Uncontrolled hypertension indicate systolic blood pressure &gt; 170 mmHg OR diastolic blood pressure &gt; 105 mmHg Severe concurrent disease , infection , comorbidity , judgment investigator , would make patient inappropriate enrollment ( e.g . uncontrolled acute severe infection , advance chronic obstructive pulmonary disease , heart failure ) Known history HIV , hepatitis B , hepatitis C Major surgery within 4 week prior registration Gastrointestinal disorder affect absorption ( e.g. , gastrectomy , active peptic ulcer disease within 3 month prior registration ) Treatment metformin within last 6 month prior registration Patients pharmacotherapy diabetes mellitus History diabetic ketoacidosis , diabetic coma precoma Known history seizure condition may predispose seizure . History loss consciousness transient ischemic attack within 12 month prior registration Concurrent anticoagulation rivaroxaban warfarin Known hypersensitivity IMPs hypersensitivity component Any concomitant drug contraindicate use IMPs accord Swissmedic approve product information Any psychological , familial , sociological geographical condition potentially hamper compliance trial protocol followup .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Cancer prostate</keyword>
	<keyword>Metformin</keyword>
	<keyword>Enzalutamide</keyword>
	<keyword>Xtandi</keyword>
	<keyword>castration resistant prostate cancer</keyword>
	<keyword>phase II</keyword>
	<keyword>Androgen deprivation therapy</keyword>
</DOC>